Enhanced Vaccine for Necrotic Enteritis in Poultry
Legal Citation
Summary of the Inventive Concept
An improved vaccine composition and delivery system for protecting poultry from necrotic enteritis, offering enhanced safety, efficiency, and immune response.
Background and Problem Solved
The original patent disclosed a vaccine for preventing necrotic enteritis in poultry, but it had limitations in terms of immune response, safety, and production efficiency. The new inventive concept addresses these limitations by introducing an adjuvant-enhanced vaccine composition, a co-administered adjuvant for immune response enhancement, a plant-based expression system for production, a mutated non-toxic NetB toxin, and an oral vaccine delivery system.
Detailed Description of the Inventive Concept
The enhanced vaccine composition comprises a PlcC-NetB fusion protein and an adjuvant, which stimulates a stronger immune response against the NetB toxin. The co-administered adjuvant enhances the production of antibodies against the NetB toxin, providing better protection against necrotic enteritis. The plant-based expression system enables more efficient and cost-effective production of the PlcC-NetB fusion protein. The mutated non-toxic NetB toxin retains its immunogenic properties while eliminating the risk of toxicity. The oral vaccine delivery system facilitates easier administration and uptake of the vaccine by poultry.
Novelty and Inventive Step
The new claims introduce a novel adjuvant-enhanced vaccine composition, a co-administered adjuvant, a plant-based expression system, a mutated non-toxic NetB toxin, and an oral vaccine delivery system, which are not obvious from the original patent and provide significant improvements over the existing vaccine.
Alternative Embodiments and Variations
Alternative embodiments may include different adjuvants, expression systems, or delivery vehicles. Variations may involve using different protein units, linkers, or mutations to achieve similar improvements in immune response, safety, and efficiency.
Potential Commercial Applications and Market
The enhanced vaccine composition and delivery system have significant commercial potential in the poultry industry, offering improved protection against necrotic enteritis, reduced mortality rates, and increased productivity. The target market includes poultry farms, vaccine manufacturers, and animal health companies.
CPC Classifications
| Section | Class | Group |
|---|---|---|
| A | A61 | A61K39/08 |
| A | A61 | A61P31/04 |
| C | C12 | C12N15/74 |
| C | C12 | C12N15/8258 |
| A | A61 | A61K2039/552 |
| A | A61 | A61K2039/55577 |
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Veterinary immunology and vaccine development, specifically focused on poultry disease prevention, with expertise in protein engineering, microbiology, and immunological techniques
Person of Ordinary Skill (PHOSITA) Profile
A researcher with advanced degrees in veterinary science or microbiology, experienced in protein fusion technologies, vaccine design, and understanding of bacterial toxin mechanisms, familiar with molecular cloning and immunological assays
Obviousness Rationale
A person of ordinary skill would recognize that the PTD's variations represent predictable extensions of the source patent's core vaccine technology. The fusion protein concept, toxin modification, and adjuvant enhancement are logical incremental improvements that would be apparent to a skilled researcher working in poultry vaccine development. The technical solutions proposed are consistent with established strategies for improving vaccine efficacy and safety.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,613 |
|---|---|
| Title | Vaccine for prevention of necrotic enteritis in poultry |
| Assignee(s) | Arizona Board of Regents on Behalf of Arizona State University |